Sierra Oncology, Inc. (SRRA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sierra Oncology, Inc. (SRRA) trades at $54.99 with AI Score 41/100 (Grade C). Sierra Oncology, Inc. is a late-stage biopharmaceutical company focused on researching, developing, and commercializing therapies for hematology and oncology needs. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for SRRA: SRRA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SRRA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SRRA: 2/3 scored disciplines lean bearish. Dominant signal: Moon AI bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sierra Oncology, Inc. (SRRA) Healthcare & Pipeline Overview
Sierra Oncology, Inc. is a biopharmaceutical firm specializing in hematology and oncology therapies, with its lead drug momelotinib targeting key kinase inhibitors. Acquired by GSK plc in July 2022, Sierra Oncology continues to develop treatments for patients with unmet needs in myelofibrosis and related cancers, operating within the competitive biotechnology sector.
What Is the Investment Thesis for SRRA?
Sierra Oncology, now a subsidiary of GSK plc, presents an investment case centered on the potential of momelotinib in treating myelofibrosis. Momelotinib's unique mechanism of action, inhibiting JAK1, JAK2, and ACVR1, offers a differentiated approach to managing the disease. Key value drivers include successful commercialization of momelotinib, expansion into new indications, and pipeline development of SRA515 and SRA737. The company's negative P/E ratio of -7.70 reflects its status as a development-stage company. Upcoming catalysts include regulatory milestones and clinical trial results. Potential risks include competition from existing therapies and the inherent uncertainties in drug development.
Based on FMP financials and quantitative analysis
SRRA Key Highlights
Momelotinib is a selective and orally bioavailable JAK1, JAK2, and ACVR1 inhibitor targeting myelofibrosis.
- Sierra Oncology was acquired by GSK plc in July 2022, enhancing its resources and development capabilities.
- The company is developing SRA515, a selective bromodomain-containing protein 4 inhibitor, for cancer treatment.
- Sierra Oncology has license agreements with Carna Biosciences, AstraZeneca AB, and CRT Pioneer Fund LP to develop novel therapies.
- The company's lead drug candidate addresses unmet needs in myelofibrosis, a rare bone marrow cancer.
Who Are SRRA's Competitors?
SRRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
| CINC CinCor Pharma, Inc. | $29.06 | +0.00% | $1.27B | 47 |
| CTIC CTI BioPharma Corp. | $9.10 | +0.06% | $1.20B | 56 |
| EQRX EQRx, Inc. | $2.34 | -2.09% | $1.14B | — |
| ETHZ ETHZ | $3.53 | +0.00% | $56.4M | 52 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SRRA's Key Strengths?
Proprietary drug candidates with unique mechanisms of action.
- Strong intellectual property protection for its therapies.
- Acquisition by GSK plc provides significant resources and expertise.
- Experienced management team with a track record of success.
What Are SRRA's Weaknesses?
Reliance on a limited number of drug candidates.
- High research and development costs.
- Lengthy regulatory approval processes.
- Dependence on GSK plc for funding and support.
What Could Drive SRRA Stock Higher?
Regulatory approval decisions for momelotinib in key markets (2026-2027).
- Clinical trial results for SRA515 in Phase 1 studies (2027-2028).
- Continued commercialization of momelotinib by GSK plc.
- Expansion of momelotinib into new indications through clinical trials.
What Are the Key Risks for SRRA?
Negative return on equity (-97.6%) — the business is not currently generating profit on shareholder capital.
- Competition from existing and emerging therapies for myelofibrosis.
- Uncertainties in drug development and regulatory approval processes.
- Reliance on GSK plc for funding and support.
- High research and development costs.
What Are the Growth Opportunities for SRRA?
- Expansion of Momelotinib into New Indications: Sierra Oncology has the opportunity to expand the use of momelotinib beyond myelofibrosis into other related hematological malignancies. This could significantly increase the addressable patient population and drive revenue growth. The market for targeted therapies in hematological cancers is estimated to reach $30 billion by 2030, presenting a substantial opportunity for Sierra Oncology. Clinical trials are ongoing to evaluate momelotinib in these new indications, with results expected over the next 2-3 years.
- Development of SRA515: SRA515, a selective bromodomain-containing protein 4 inhibitor, represents a promising growth opportunity for Sierra Oncology in the broader oncology market. Bromodomain inhibitors have shown potential in treating various solid tumors and hematological malignancies. The global market for bromodomain inhibitors is projected to reach $1.5 billion by 2028. Sierra Oncology plans to initiate Phase 1 clinical trials for SRA515 in 2027, with potential for accelerated approval pathways based on early clinical data.
- Commercialization in New Geographic Markets: Sierra Oncology, with the backing of GSK plc, has the opportunity to expand the commercialization of momelotinib into new geographic markets, particularly in Europe and Asia. These regions have a growing demand for advanced cancer therapies and represent a significant untapped market. The company plans to seek regulatory approval for momelotinib in these regions over the next 3-5 years, leveraging GSK's global infrastructure and expertise.
- Strategic Partnerships and Acquisitions: Sierra Oncology can pursue strategic partnerships and acquisitions to expand its pipeline and access new technologies. Collaborating with other biotechnology companies or acquiring promising drug candidates can accelerate its growth and diversify its portfolio. The company is actively evaluating potential opportunities in the oncology space, with a focus on innovative therapies and novel targets. These partnerships could materialize within the next 1-2 years.
- Advancements in Personalized Medicine: Sierra Oncology can leverage advancements in personalized medicine to develop more targeted and effective therapies. By identifying specific biomarkers and genetic profiles, the company can tailor treatments to individual patients, improving outcomes and reducing side effects. The market for personalized medicine in oncology is rapidly growing, driven by advances in genomics and diagnostics. Sierra Oncology plans to integrate personalized medicine approaches into its clinical trials and drug development programs over the next 5 years.
What Are SRRA's Competitive Advantages?
- Proprietary drug candidates with unique mechanisms of action.
- Strong intellectual property protection for its therapies.
- Established partnerships with leading biotechnology companies.
- Expertise in drug development and commercialization.
What Does SRRA Do?
Sierra Oncology, Inc., established in 2003 and formerly known as ProNAi Therapeutics, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapies for patients with hematological and oncological disorders. The company's focus is on addressing unmet needs in myelofibrosis and other related cancers. Sierra Oncology's lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. This drug is designed to treat the underlying causes of myelofibrosis, a rare bone marrow cancer. In addition to momelotinib, Sierra Oncology is developing SRA515, a selective bromodomain-containing protein 4 inhibitor, and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. These compounds represent potential treatments for a range of cancers. Sierra Oncology has also established license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7, as well as agreements with AstraZeneca AB and CRT Pioneer Fund LP. As of July 1, 2022, Sierra Oncology operates as a subsidiary of GSK plc, which acquired the company to bolster its oncology pipeline.
What Products and Services Does SRRA Offer?
- Researches and develops therapies for hematological and oncological disorders.
- Focuses on unmet needs in myelofibrosis and related cancers.
- Develops momelotinib, a JAK1, JAK2, and ACVR1 inhibitor.
- Develops SRA515, a selective bromodomain-containing protein 4 inhibitor.
- Develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1.
- Establishes license agreements with other biotechnology companies.
How Does SRRA Make Money?
- Develops and commercializes pharmaceutical products.
- Generates revenue through the sale of its therapies.
- Partners with other companies for research and development.
- Out-licenses its technologies to generate revenue.
What Industry Does SRRA Operate In?
Sierra Oncology operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for myelofibrosis treatments is growing, driven by an aging population and increased diagnosis rates. Key trends in the industry include the development of targeted therapies and personalized medicine. Sierra Oncology's momelotinib competes with existing JAK inhibitors, but its unique mechanism of action offers a potential advantage. The company's acquisition by GSK plc provides it with greater resources and expertise to navigate the competitive landscape.
Who Are SRRA's Key Customers?
- Patients with hematological and oncological disorders.
- Healthcare providers who prescribe and administer the company's therapies.
- Hospitals and clinics that purchase the company's products.
- Pharmaceutical distributors who distribute the company's products.
Company Profile
Sierra Oncology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Nicholas Glover. SRRA has traded publicly since 2015.
How Sierra Oncology, Inc. Is Valued
Relative to its peer group, SRRA's quantitative score of 41/100 is below the peer average of 57/100.
Key Financial Metrics
Return on equity for Sierra Oncology, Inc. stands at -97.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -86.6%, showing how much profit it generates from its asset base. A current ratio of 8.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.0%, the inverse of the P/E and a quick read on earnings relative to price.
SRRA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary drug candidates with unique mechanisms of action.
- Strong intellectual property protection for its therapies.
- Acquisition by GSK plc provides significant resources and expertise.
- Experienced management team with a track record of success.
Bear Case
- Reliance on a limited number of drug candidates.
- High research and development costs.
- Lengthy regulatory approval processes.
- Dependence on GSK plc for funding and support.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SRRA Latest News
No recent news available for SRRA.
SRRA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SRRA.
Price Targets
Wall Street price target analysis for SRRA.
SRRA MoonshotScore
What does this score mean?
The MoonshotScore rates SRRA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Nicholas Glover
CEO
Nicholas Glover serves as the CEO of Sierra Oncology, Inc. He has extensive experience in the biopharmaceutical industry, with a focus on oncology drug development and commercialization. Prior to joining Sierra Oncology, Mr. Glover held leadership positions at various biotechnology companies, where he oversaw clinical trials, regulatory submissions, and product launches. He has a strong track record of building and managing successful teams. His expertise spans across multiple therapeutic areas, including hematology and oncology.
Track Record: Under Nicholas Glover's leadership, Sierra Oncology achieved significant milestones, including the advancement of momelotinib through late-stage clinical trials and its subsequent acquisition by GSK plc. He played a key role in securing partnerships and collaborations to expand the company's pipeline. His strategic decisions have positioned Sierra Oncology as a leader in the development of therapies for myelofibrosis and other related cancers.
Common Questions About SRRA (Healthcare)
What does the AI Score mean for SRRA?
SRRA holds an AI Score of 41/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Sierra Oncology, Inc. is a late-stage biopharmaceutical company focused on researching, developing, and commercializing therapies for hematology and oncology needs. Their lead drug candidate …
What does Sierra Oncology, Inc. do?
Sierra Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with hematological and oncological disorders, particularly myelofibrosis. Their lead drug candidate, momelotinib, is a selective JAK1, JAK2, and ACVR1 inhibitor designed to address the underlying causes of myelofibrosis. Acquired by GSK plc in July 2022, Sierra Oncology continues to advance its pipeline and expand the potential applications of momelotinib and other drug candidates.
What do analysts say about SRRA stock?
As of March 18, 2026, Sierra Oncology is a subsidiary of GSK plc and is no longer traded as an independent entity. Prior to the acquisition, analyst consensus was generally positive regarding the potential of momelotinib and the company's pipeline. Key valuation metrics included the potential peak sales of momelotinib and the overall market opportunity in myelofibrosis. Growth considerations centered on successful commercialization and expansion into new indications.
What are the main risks for SRRA?
The main risks for Sierra Oncology, now under GSK plc, include competition from existing and emerging therapies for myelofibrosis, uncertainties in drug development and regulatory approval processes, and reliance on GSK plc for funding and support. Additionally, high research and development costs and potential changes in regulatory requirements pose ongoing challenges. Successful commercialization of momelotinib remains a key factor in mitigating these risks.
What revenue streams does Sierra Oncology, Inc. have in healthcare?
Sierra Oncology, Inc.'s revenue streams are primarily derived from the commercialization of its therapies for hematological and oncological disorders, with momelotinib being the key revenue driver. Post-acquisition by GSK plc, the revenue generated by Sierra Oncology's products is integrated into GSK's overall financial performance. The revenue is influenced by factors such as market penetration, pricing strategies, and geographic expansion.
What are the key growth opportunities for SRRA in healthcare?
Key growth opportunities for Sierra Oncology, now a part of GSK plc, include expanding the use of momelotinib into new therapeutic areas beyond myelofibrosis, such as other related hematological malignancies. Additionally, the development of SRA515 and SRA737 represents potential growth drivers in the broader oncology market.
What are the key factors to evaluate for SRRA?
Sierra Oncology, Inc. (SRRA) holds an AI score of 41/100 (low). Sierra Oncology, now a subsidiary of GSK plc, presents an investment case centered on the potential of momelotinib in treating myelofibrosis. Not financial advice.
How frequently does SRRA data refresh on this page?
SRRA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SRRA's recent stock price performance?
Sierra Oncology, Inc. (SRRA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug candidates with unique mechanisms of action. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 18, 2026.
- Sierra Oncology is now a subsidiary of GSK plc, which may impact its future strategies and financial performance.